<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04896385</url>
  </required_header>
  <id_info>
    <org_study_id>INCB 18424-214</org_study_id>
    <nct_id>NCT04896385</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Mechanism of Action of Ruxolitinib Cream in Subjects With Vitiligo (TRuE-V MOA)</brief_title>
  <official_title>A Randomized, Double-Blind, Vehicle-Controlled Study to Evaluate the Mechanism of Action of Ruxolitinib Cream for Vitiligo</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Incyte Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Incyte Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the Mechanism Of Action (MOA) of ruxolitinib cream in&#xD;
      vitiligo by assessing the change in biomarkers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 23, 2021</start_date>
  <completion_date type="Anticipated">March 26, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 23, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Randomized, double-blind, vehicle-controlled, with an open-label treatment extension.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate change in Immune Biomarkers</measure>
    <time_frame>First 24 weeks of study</time_frame>
    <description>Percentage change from baseline in immune biomarkers, including CXCL10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation of CXCL10 biomarker to Vitiligo Area Scoring Index (VASI) Repigmentation response in target lesions</measure>
    <time_frame>First 24 weeks of study</time_frame>
    <description>Defined as correlation of change in biomarkers to VASI repigmentation measured at weeks 12 and 24.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatment emergency Adverse Events</measure>
    <time_frame>56 weeks</time_frame>
    <description>Adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug/treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Vitiligo</condition>
  <arm_group>
    <arm_group_label>Ruxolitinib cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ruxolitinib cream will be administered twice a day (BID) for 24 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle Cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruxolitinib cream</intervention_name>
    <description>Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.</description>
    <arm_group_label>Ruxolitinib cream</arm_group_label>
    <other_name>INCB018424 cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle Cream</intervention_name>
    <description>Vehicle cream is matching in appearance to ruxolitinib cream and is to be applied in the same manner as ruxolitinib cream.</description>
    <arm_group_label>Vehicle Cream</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  A clinical diagnosis of nonsegmental vitiligo with depigmented areas including ≥ 0.5%&#xD;
             BSA on the face, ≥ 0.5 F-VASI, ≥ 3% BSA on nonfacial areas, and ≥ 3 T-VASI; total body&#xD;
             vitiligo area (facial and nonfacial) should not exceed 50% BSA.&#xD;
&#xD;
          -  At least 1 active vitiligo lesion (eg, such as confetti lesion, trichrome appearance,&#xD;
             pinkish rim, or other evidence of inflammatory activity) at the site for skin biopsy.&#xD;
&#xD;
          -  Agree to discontinue all agents used to treat vitiligo from screening through the&#xD;
             final safety follow-up visit. Over-the-counter preparations deemed acceptable by the&#xD;
             investigator and camouflage makeups are permitted.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  No pigmented hair within any of the vitiligo areas on the face.&#xD;
&#xD;
          -  Other forms of vitiligo (eg, segmental) or other differential diagnosis of vitiligo or&#xD;
             other skin depigmentation disorders (eg, piebaldism, pityriasis alba, leprosy,&#xD;
             postinflammatory hypopigmentation, progressive macule hypomelanosis, nevus anemicus,&#xD;
             chemical leukoderma, and tinea versicolor).&#xD;
&#xD;
          -  Used depigmentation treatments (eg, monobenzone) for past treatment of vitiligo or&#xD;
             other pigmented areas except hydroquinone.&#xD;
&#xD;
          -  Any other skin disease that, in the opinion of the investigator, would interfere with&#xD;
             the study medication application or study assessments.&#xD;
&#xD;
          -  Conditions at baseline that would interfere with evaluation of vitiligo.&#xD;
&#xD;
          -  Use of any protocol-defined treatments within the indicated washout period before&#xD;
             baseline.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Incyte Corporation Call Center (US)</last_name>
    <phone>1.855.463.3463</phone>
    <email>medinfo@incyte.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Incyte Corporation Call Center (ex-US)</last_name>
    <phone>+800 00027423</phone>
    <email>eumedinfo@incyte.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>First Oc Dermatology</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <zip>92708</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UC Irvine</name>
      <address>
        <city>Irvine</city>
        <state>California</state>
        <zip>92697</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialists of Spokane</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Institute</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T1Y 0B4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Simcoderm Medical and Surgical Dermatology Center</name>
      <address>
        <city>Barrie</city>
        <state>Ontario</state>
        <zip>L4M 7G1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Lynderm Research Inc</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jbr Research Inc</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 7X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 30, 2021</study_first_submitted>
  <study_first_submitted_qc>May 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2021</study_first_posted>
  <last_update_submitted>November 10, 2021</last_update_submitted>
  <last_update_submitted_qc>November 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Vitiligo</keyword>
  <keyword>depigmenting disorder</keyword>
  <keyword>topical JAK inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitiligo</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.</ipd_time_frame>
    <ipd_access_criteria>Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://www.incyte.com/our-company/compliance-and-transparency</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

